Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06053047 · ClinicalTrials.gov registry record · NA
Remote Monitoring of the Diabetic Foot to Prevent Re-Ulceration
A NA study, sponsored by Bluedrop Medical Limited.
- Terminated
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT06053047: Clinical Trial NA study, sponsored by Bluedrop Medical Limited.
NCT06053047 is a NA study that was terminated before completion, run by Bluedrop Medical Limited. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06053047, a NA study, was terminated before completion, sponsored by Bluedrop Medical Limited.
- TERMINATED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the effects of the Bluedrop Monitoring System (BMS) on the development of diabetic foot ulcers. All Participants in this study will continue with their normal foot care and complete surveys with questions about their foot health every three months. Participants selected to receive the Bluedrop Monitoring System (BMS) will place it in their home and stand on it once a day for 12 months. Participants will also need to answer questions about their general foot health and, if using the system, their experience using the device and monitoring service.
Primary Outcome
Relative risk reduction in the incidence of new Diabetic Foot Ulcers (DFUs) (Wound Stage 2 or 3 as defined by University of Texas Staging System for Diabetic Foot Ulcers where a higher score is a worse outcome \<min score of 0 and max score of 3\>) in participants assigned to use of the BMS compared to those not assigned to use of the BMS
Interventions
- DEVICE Bluedrop Monitoring Service (BMS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2024-09-18 |
| Phase | NA |
Why NCT06053047 stopped before completion
NCT06053047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Bluedrop Monitoring Service (BMS) is the first listed.
NCT06053047 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06053047 about?
NCT06053047 is a clinical study titled "Remote Monitoring of the Diabetic Foot to Prevent Re-Ulceration". The purpose of this study is to understand the effects of the Bluedrop Monitoring System (BMS) on the development of diabetic foot ulcers. All Participants in this study will continue with their normal foot care and complete surveys with questions about their foot health every three months. Partic...
What is the current status of trial NCT06053047?
This trial is currently terminated. It is a NA study. The enrollment target is 26 participants. The study started on 2024-01-22. Estimated completion is 2024-09-18.
What interventions are being tested in trial NCT06053047?
The interventions under investigation include: Bluedrop Monitoring Service (BMS) (DEVICE).
Who is sponsoring clinical trial NCT06053047?
This trial is sponsored by Bluedrop Medical Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06053047's enrollment target sits among peer trials
26 1710th of 2000 higher than 289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI